Mexico Antirheumatic Drugs market was valued at US$2,389.634 million in 2019. Rising Mexican population suffering from arthritis is the major driver of the antirheumatic drugs market in Mexico. Arthritis does not affect only the elderly population, lifestyle, and work influence also results in the development of arthritis in adults. As such, the growing working population with a sitting job is also leading to the rising prevalence of arthritis in Mexico, thereby fuelling the antirheumati Read more...
Saudi Arabia antirheumatic drugs market was valued at US$517.880 million in 2019. The antirheumatic drugs market in Saudi Arabia is projected to show nominal growth throughout the forecast period owing to the low prevalence of arthritis in the country. However, the growth in the country may be attributed to the presence of a state-of-art healthcare system of the country. Saudi Arabia is one of the most prominent countries of the MEA region Saudi Arabian region regarding the development o Read more...
South America Antirheumatic Drugs market was valued at US$7,074.415 million in 2019. Countries like Brazil, Argentina, Peru, and Colombia are witnessing a continuous rise in the number of people suffering from chronic diseases. According to the World Health Organization, the total prevalence of diabetes in Argentina is 10.2% of the country’s total population. As such, the prevalence of arthritis is also increasing in the region, thus driving the antirheumatic drugs market in South Read more...
South Korea antirheumatic drugs market was valued at US$663.833 million in 2019. The growth of the marketin this country is majorly attributed to the growing geriatric population on account of a good healthcare system across the country. According to data from the World Bank Group, the proportion of South Korean population aged 65 and above was 7.51% in 2001, and this number had risen to 14.42% in 2018. Since this age group is more prone to getting rheumatoid arthritis, and even if someo Read more...
Spain antirheumatic drug market was valued at US$800.242 million in 2019. Spain is the 14th largest economy in the world and the 5th in the European Union, even after years of economic recession Spain marked the third straight year of at least 3% of GDP growth becoming one of the fastest-growing economies in the European Union and recently country is developed into one of the top players in the European pharmaceutical industry. The pharmaceutical industry has been increasing its investme Read more...
France Antirheumatic drugs market was valued at US$1,095.785 million in 2019. The antirheumatic drugs market in France is poised to grow on account of the high government support in the country for providing better healthcare services to the citizens along with the presence of a well-established healthcare sector of the country. The majority of the health expenditure of the country is government-funded which further enables the citizens to afford costly treatments and medicines which is Read more...
Brazilian Antirheumatic Drugs market was valued at US$4,495.339 million in 2019. The growing aging population in Brazil is the major factor that is driving the demand for antirheumatic drugs in the country. Recovery of the Brazilian economy can be witnessed by increasing purchasing power and corresponding shift towards a fast-food diet, leading to rising cases of obesity and diabetes in the country. According to the World Health Organization (WHO), the prevalence of diabetes has increase Read more...
United States Antirheumatic Drugs market was valued at US$5,913.744 million in 2019. As per the data from the World Bank Group, the population of ages 65 and above has increased from 40,156,009 in 2010 to 51,717,496 by 2018.With the booming geriatric population in the U.S, the demand for antirheumatic drugs in the country is poised to grow during the forecast period. Moreover, the rising number of adults with arthritis is also driving the market growth of antirheumatic drug market in the Read more...
The United Kingdom antirheumatic drugs market was valued at US$1,109.524 million in 2019. The market in the United Kingdom is projected to show a nominal growth over the next five years on account of the high prevalence of rheumatic diseases in the country coupled with the presence of a world-class healthcare sector of the country. According to the United Kingdom National Health Service, more than 10 million people in the country suffer from arthritis and numerous conditions. This, in tu Read more...
The global hydroxychloroquine drugs market is projected to grow at a CAGR of 3.08% to reach US$1,174.129 million by 2025, from US$978.745 million in 2019. Rising prevalence of chronic rheumatoid conditions, malaria, and lupus among the individuals is pushing the demand for hydroxychloroquine drugs. According to the World Health Organization (WHO), there are approximately 150 diseases or more that come under Rheumatic or musculoskeletal condition that are associated with different degr Read more...
.jpg)
